Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: Simvastatin in Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial of simvastatin for Waldenström's macroglobulinemia was terminated, with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-12-16Clinical Trial Update: CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial of lenalidomide plus rituximab in Waldenström's macroglobulinemia was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies [Phase 1]
Phase 1 safety study of carfilzomib (PR-171) in hematologic malignancies has completed and results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of lenalidomide plus rituximab as maintenance therapy for adult B-cell non-Hodgkin lymphoma is noted as terminated.
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia [Phase 3]
A Phase 3 trial compares chlorambucil with fludarabine in patients with advanced Waldenström macroglobulinemia. The study also covers lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease [Phase 2]
Phase 2 trial update reporting completion of a study evaluating interleukin-12 in patients with various previously treated non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
A SWOG trial (NCT00919139) evaluating a blood/bone marrow repository from patients with multiple myeloma, smoldering myeloma, Waldenström's …
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating high-dose melphalan with peripheral stem cell transplantation followed by interferon alfa in Waldenström's macroglo…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia [Phase 2]
A Phase 2 trial of bortezomib, dexamethasone, and rituximab in untreated Waldenström macroglobulinemia has been completed. The update notes …
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This ClinicalTrials.gov update reports a terminated phase 1/2 trial evaluating fenretinide with rituximab for B-cell non-Hodgkin lymphomas; …
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update evaluating the combination of iodine-131 tositumomab with fludarabine phosphate in older patients undergoing autologous…
-
CLINICAL_TRIALS trial_result · 2014-06-16Clinical Trial Update: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 clinical trial of everolimus (RAD001) as primary therapy for Waldenstrom's Macroglobulinemia completed with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial evaluating thalidomide plus rituximab in Waldenström's macroglobulinemia has completed, with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [Phase 1]
Phase 1 study of MK-2206 in pediatric patients with recurrent or refractory solid tumors or leukemias has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating CCI-779 (temsirolimus) in patients with recurrent or refractory B-cell non-Hodgkin lymphoma or chronic l…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma [Phase 3]
A Phase 3 trial evaluating chlorambucil versus fludarabine as first-line therapy for previously untreated Waldenström macroglobulinemia, spl…
-
CLINICAL_TRIALS trial_result · 2013-08-16Clinical Trial Update: Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating Rituximab for Waldenström macroglobulinemia has completed. The study was conducted by the Eastern Cooperative Onc…
-
CLINICAL_TRIALS trial_result · 2013-08-02Clinical Trial Update: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia [Phase 1]
A Phase 1 dose-escalation study of MLN0128 in relapsed or refractory multiple myeloma and Waldenström macroglobulinemia has completed.
-
CLINICAL_TRIALS trial_result · 2013-07-02Clinical Trial Update: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies [Phase 1]
A Phase 1 dose-escalation study of TAK-901 in subjects with advanced hematologic malignancies; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-26Clinical Trial Update: Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial of Dolastatin 10 in patients with indolent non-Hodgkin lymphoma, Waldenström's macroglobulinemia, or chronic lymphocytic leuke…